THE ROLE OF HEPATITIS-C VIRUS IN CHRONIC HEPATITIS-B VIRUS-INFECTION

被引：31

作者：

CHUANG, WL ^{[1
]}

CHANG, WY ^{[1
]}

LU, SN ^{[1
]}

LIN, ZY ^{[1
]}

CHEN, SC ^{[1
]}

HSIEH, MY ^{[1
]}

WANG, LY ^{[1
]}

YOU, SL ^{[1
]}

CHEN, CJ ^{[1
]}

机构：

[1] KAOHSIUNG MED COLL,DEPT INTERNAL MED,100 SHIH CHUAN 1ST RD,KAOHSIUNG 80708,TAIWAN

来源：

GASTROENTEROLOGIA JAPONICA | 1993年 / 28卷

关键词：

D O I：

10.1007/BF02989199

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

To investigate the influence of hepatitis C virus (HCV) infection on patients with chronic hepatitis B virus (HBV), the presence of antibody against C100-3 antigen of HCV (anti-HCV) was examined in 420 patients with chronic HBV infection and 275 healthy subjects. It was found that the prevalence of HCV infection increased in parallel with the severity of liver damage. The positive rates of anti-HCV were as follows: healthy subjects, 2.9% (8/275); asymptomatic carriers, 2.6% (5/193); chronic hepatitis, 5.2% (3/58); liver cirrhosis, 11.4% (8/70); hepatocellular carcinoma (HCC), 12.1% (12/99). To elucidate the interaction of these two viruses in hepatocellular carcinoma, 128 HCC patients and 384 age-matched and sex-matched subjects were further analyzed. Eighty-seven of 128 HCC patients (68.0%) were only positive for HBsAg, 13 patients (10.1%) were only anti-HCV positive, and 12 (9.4%) were positive for both markers. The presence of HBsAg and anti-HCV was associated strongly with HCC. Moreover, the risk of HCC was significantly higher when both HBsAg and anti-HCV were present simultaneously. These results suggested that concurrent HCV infection might accelerate the progression of chronic HBV infection and may contribute to the pathogenesis of HCC in patients with chronic HBV infection. © 1993 The Japanese Society of Gastroenterology.

引用

页码：23 / 27

页数：5

共 23 条

[1]

Kuo G., Choo Q.L., Alter H.J., Et al., An assay for circulating antibodies to a major etiologic virus for human non-A, non-B hepatitis, Science, 244, pp. 362-364, (1989)

[2]

Alter H.J., Purcell R.H., Shih J.W., Et al., Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis, N Engl J Med, 321, pp. 1494-1500, (1989)

[3]

Sherlock S., Viral hepatitis, Diseases of the Liver and Biliary System, pp. 301-338, (1989)

[4]

Villa E., Baldini G.M., Pasquinelli C., Et al., Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol, Cancer, 62, pp. 611-615, (1988)

[5]

Sakamoto M., Hirohashi S., Tsuda H., Et al., Increasing incidence of hepatocellular carcinoma possibly associated with non-A, non-B hepatitis in Japan, disclosed by hepatitis B virus DNA analysis of surgically resected cases, Cancer Res, 48, pp. 7294-7297, (1988)

[6]

Esteban J.I., Esteban R., Viladomiu L., Et al., Hepatitis C virus antibodies among risk groups in Spain, Lancet, 2, pp. 294-297, (1989)

[7]

Vargas V., Castells L., Esteban J.I., High frequency of antibody to hepatitis C virus among patients with hepatocellular carcinoma, Ann Intern Med, 112, pp. 232-233, (1990)

[8]

Sbolli G., Zanetti A.R., Tanzi E., Et al., Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma, J Med Virol, 30, pp. 230-232, (1990)

[9]

Bruix J., Barrera J.M., Calvet X., Et al., Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis, Lancet, 2, pp. 1004-1006, (1989)

[10]

Colombo M., Kuo G., Choo Q.L., Et al., Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma, Lancet, 2, pp. 1006-1008, (1989)

← 1 2 3 →